SupportLoginSign Up
Featured FeedJournalsCollectionsKeywords
JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Subepyndemal hemangioblastomas of the cervicomedullary junction: lessons learned in the management of two cases.

John S Winestone, Julian Lin, Robert A Sanford, Frederick A Boop
Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery 2007 July
OBJECTIVE: This retrospective case series analyzes two cases of hemangioblastomas in the cervicomedullary junction.

METHODS: A survey of the pediatric staff and of the operative reports from medical records with a review of the literature and medical records of patients with the condition was conducted.

RESULTS: Two patients were successfully treated surgically.

CONCLUSION: Surgery is the treatment of choice for hemangioblastomas of the cervicomedullary junction. Careful monitoring for unique complications, treatment of the tumor as a vascular malformation, and screening for von Hippel Lindau must all be employed to safely care for this challenging group of patients.

Full text links

Find Full Text Links for this Article

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Do Not Sell My Personal InformationManage Cookie Preferences

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app